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It has been reported that hepatitis C virus (HCV) infection is closely associated with hepatic metabolic disorders. Hepatic steatosis
and insulin resistance are both relatively common in patients with chronic hepatitis C. Recent investigations suggest that HCV
infection changes the expression proﬁle of lipid-metabolism-associated factors in the liver, conferring advantages to the life cycle
of HCV. Moreover, insulin resistance and steatosis are independent predictors of impaired response to antiviral treatment in
chronic hepatitis C. In this paper, we summarize our current knowledge of hepatic metabolic disorders and describe how HCV
leads to and exploits these hepatic disorders. We also discuss the clinical signiﬁcance of insulin sensitizers used to improve insulin
resistance and lipid modulators used to manage lipid metabolism as potential treatment options for chronic hepatitis C.
1.Introduction
Hepatic steatosis is a well-documented histological charac-
teristic of chronic hepatitis C virus (HCV) infection [1].
Insulin resistance or impaired glucose metabolism, is linked
to hepatic steatosis in patients with chronic hepatitis C (CH-
C). It is widely considered that hepatic steatosis in patients
with CH-C is caused by lipid metabolic disorders, in which
insulin resistance plays an important role [2]. Fat accumu-
lation promotes oxidative stress and inﬂammatory reactions.
A considerable number of studies have also suggested that
various HCV proteins lead to alterations in lipid synthesis,
catabolism and transport. In particular, HCV core protein
was reported to contribute to these metabolic changes and
induce reactive oxygen species generation [3, 4]. Clinically,
hepatic steatosis and insulin resistance in CH-C patients are
associated with hepatic ﬁbrosis, an increased frequency of
hepatocellular carcinoma, and a poor response to pegylated
interferon(peg-IFN)plusribavirincombinationtherapy[5].
2. HCVInfection andInsulinResistance
It has been reported that hepatic steatosis is correlated with
viral load; approximately 50% of patients with CH-C have
hepatic steatosis, which enhances disease progression [6, 7].
Recent studies have shown that, as in nonalcoholic fatty
liver disease (NAFLD), insulin resistance and an increased
fatty acid supply to the liver are important pathogeneses of
steatosis in CH-C [8]. In CH-C patients, the occurrence of
insulin resistance is independent of visceral adipose tissue
and hepatic steatosis and irrespective of the HCV genotype
[9]. In our experience, insulin resistance is frequently
observed in nonobese patients, and 36.8% patients with CH-
C had a homeostasis model assessment-insulin resistance
(HOMA-IR) index ≥2.5 [10]. Even though the association
between the severity of insulin resistance and HCV viral load
or genotype is controversial, viral eradication by antiviral
therapyactuallyimprovesinsulinsensitivity[11–13].Despite
the close association between chronic HCV infection and the
presence of insulin resistance, the pathogenic basis of this2 International Journal of Hepatology
interaction remains to be elucidated. Increasing epidemio-
logical and experimental data suggest that the HCV core
protein impairs insulin signaling, mostly by activating tumor
necrosis factor α (TNFα) and members of the suppressor of
cytokine signaling (SOCS) family [9, 14, 15].
SOCS proteins, which are induced by proinﬂammatory
cytokines, induce proteasomal degradation of their target
proteins, including insulin receptor substrate (IRS). Exper-
imentally, upregulation of SOCS-1 and -3 in the liver leads
to insulin resistance through several mechanisms, including
degradation of IRS1 and IRS2 inhibition of insulin recep-
tor kinase activity, and downregulation of IFN-associated
innate immunity [16–18]. Activated TNFα inhibits tyrosine
phosphorylation of IRS1 and IRS2, and impairs glucose
transporter (GLUT)-4 translocation to the cell membrane,
leading to insulin resistance and hyperinsulinemia, which
can increase glycogenolysis and fatty acid synthesis [19, 20].
These changes may lead to hepatic steatosis by increas-
ing the inﬂux of free fatty acids via peripheral lipolysis,
activation of lipogenesis-associated factors, reduced fatty
acid oxidation, and decreased formation of very low-density
lipoprotein (VLDL) [21]. IRS1 and IRS2 are closely linked
to the regulation of glucokinase expression and lipogenic
enzymes, such as sterol-regulatory element-binding protein
1c (SREBP-1c), respectively.
HCV infection, mainly through activity of the HCV core
protein, decreases the expression and activity of peroxisome
proliferator-activating receptor (PPAR)-α/γ in hepatocytes
[22]. These eﬀe c t sm a yc o n s t i t u t es t r a t e g i e sf o rv i r a ls u r v i v a l
and proliferation. PPARα and PPARγ transcriptionally regu-
latefattyacidβ-oxidationandinsulinsensitivity,respectively.
Indeed, PPARγ agonists, thiazolidinediones, improve insulin
sensitivity in CH-C patients. In our earlier study, we found
that telmisartan, an angiotensin II receptor blocker and a
potential partial PPARγ agonist, had signiﬁcant therapeutic
eﬀects by attenuating insulin resistance and liver injury in
patients with CH-C [10].
3.LipidMetabolic Disordersin
HCV-InfectedLiver
A close association between HCV infection and lipid
metabolism has been reported, and host metabolic factors
and viral factors are likely to be involved in the pathogenesis
of hepatic steatosis (see Figure 1). HCV core protein, which
is localized to the membrane of lipid vesicles, induces
hepatic fat accumulation by activating SREBP-1c [23, 24].
It also inhibits microsomal triglyceride transfer protein
(MTP) activity, which is needed for VLDL assembly and
excretion [25]. HCV infection decreases hepatic expression
of PPARα, which negatively regulates fatty acid uptake and
positively regulates β-oxidation, and promotes de novo lipid
and cholesterol generation by enhancing the activities of
SREBP-1 and -2 [24, 26].
In our evaluation of the expression of lipid metabolism-
associated genes, the regulation of lipid metabolism was
impaired in HCV-infected liver [27, 28]. The expression
proﬁles revealed that HCV infection induced intrahepatic
a c c u m u l a t i o no fc h o l e s t e r o la sw e l la st r i g l y c e r i d e s ,r e s u l t i n g
in a marked reduction of low-density lipoprotein receptor
(LDLR)todecreaseLDL-cholesteroluptake,andupregulated
ATP-binding cassette G5 to increase cholesterol output.
However, de novo cholesterol and fatty acid synthesis con-
tinued to increase, perhaps because of disrupted negative
feedback pathways. This uncontrolled expression pattern is
almost similar in NAFLD [29, 30]. However, HCV core
protein interferes with the assembly and secretion of VLDL
viainactivationofMTP,leadingtohypobetalipoproteinemia,
whereas, in NAFLD, MTP activity is enhanced and hyper-
lipidemia is common [8]. This expression pattern was also
apparent in a preliminary evaluation of an HCV replicon
system.Cholesterolissynthesizedinhepatocytesthroughthe
mevalonate pathway, which is promoted by several enzymes,
including HMG-CoA reductase (HMGR). Normally, the
expressionofLDLRandHMGRisregulatedbythetranscrip-
tionfactorSREBP-2accordingtotheintracellularcholesterol
load. However, despite marked cholesterol accumulation,
HMGR expression was greatly enhanced in HCV-infected
liver [27, 28]. During cholesterol overload, the levels of
cholesterol metabolites increase, including oxysterols, which
act as agonistic ligands of liver X receptor-α (LXRα).
These metabolites activate the LXRα-SREBP1c axis, which
ultimately leads to activation of fatty acid synthesis. Notably,
LXRα expression was also enhanced in HCV-infected liver
[27, 28].
In addition to the core and nonstructural HCV proteins,
the activation of cholesterol and fatty acid biosynthesis play
a critical role in viral assembly, release, and infectivity [31–
33]. Accordingly, viral interactions with the host’s lipid
metabolic pathways appear to be essential for the life cycle
of HCV. Attachment of the virus to the cell surface LDLR
represents the ﬁrst stage of HCV entry into hepatocytes, and
β-lipoproteins inﬂuence HCV proliferation [34, 35]. Serum
HCV antigen levels are negatively correlated with serum β-
lipoprotein levels [36]. The resulting lipid droplets supply
lipoproteins and lipids and provide a site for viral assembly.
These changes seem to be necessary or beneﬁcial for HCV
replication. The mevalonate pathway of de novo cholesterol
synthesis, in which HMGR is a rate-limiting enzyme, is
also responsible for the synthesis of farnesyl pyrophosphate
and geranylgeranyl pyrophosphate that are essential for viral
replication[37].Thesemoleculesareneededtoactivatesmall
GTPases, such as Rho and Ras. Therefore, HCV may need
lipids not only as components of virus particles but also to
modulate the host’s cell signaling pathways.
4. Role of the CannabinoidSystemin
HCV-InfectedLiver
Endocannabinoids, such as anandamide and 2-arachidon-
oylglycerol (2-AG), are synthesized from lipid precursors
in cellular membranes and speciﬁcally target cannabinoid
receptors(CB)1andCB2[38].Recentstudieshavesuggested
that the hepatic cannabinoid system is involved in the patho-
genesis of NAFLD by activating CB1 and that steatogenic
factors, such as a high-fat diet, induce the synthesis ofInternational Journal of Hepatology 3
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Figure 1: Expression proﬁle of lipid metabolism-associated factors in chronic hepatitis C. ABCG5/G8, ATP-binding cassette G5/G8; FAS,
fatty acid synthase; HMGR, HMG-CoA reductase; IR, insulin receptor; IRS, insulin receptor substrate; LDLR, LDL receptor; LXRα,l i v e r
Xr e c e p t o rα; MTP, microsomal triglyceride transfer protein; NPC1L1, Niemann-Pick C1-like 1; PPARα, peroxisome proliferator-activating
receptor α; SREBP, sterol regulatory element-binding protein.
endocannabinoids and CB1 [39–41]. Although the signal
transduction pathways have not been fully characterized,
CB1 activation enhances the expression of several lipogenic
factors, including SREBP-1c and fatty acid synthase (FAS)
and downregulates factors involved in fatty acid oxidation,
such as carnitine palmitoyltransferase I, resulting in steatosis
and insulin resistance. Experimentally, steatogenic factors
appear to activate CB2, but CB2 is mostly found in immune
system cells. Therefore, CB2 activation may play a protective
role against the inﬂammatory and ﬁbrogenic responses in
steatohepatitis [42, 43].
Because daily cannabis use was proposed as a risk factor
for the severity of steatosis and progression of ﬁbrosis
in patients with CH-C [44], we determined the role of
the hepatic cannabinoid system in HCV infection using
HCV subgenomic replicon cells, which stably express viral
nonstructural proteins (NS3, NS4A/4B, NS5A, and NS5B).
Although the tested cannabinoid, anandamide, cannot be
detected in culture medium, CB1 expression and triglyceride
accumulation increased in replicon cells, as did the expres-
sionlevelsofseverallipidsynthesis-associatedgenes(SREBP-
1c, FAS, and HMGR). IFNα treatment downregulates the
expression of viral proteins and reduces triglyceride accu-
mulation and gene expression of CB1, SREBP-1c, FAS, and
HMGR. Meanwhile, treatment with a CB1 agonist increased,
and a CB1 antagonist treatment decreased triglyceride
accumulation in replicon cells.
TheseﬁndingssupportthepossibilitythatHCVinfection
activates the hepatic cannabinoid system and enhances
steatotic changes in the liver. In healthy human liver, the
hepatocytic expression of CB1 and CB2 is very low or
even absent, as are endocannabinoid levels [45–48]. Marked
upregulation of these receptors and endocannabinoid levels
(anandamide and 2-AG) has been reported in the cirrhotic
liver [45, 49–51]. Moreover, in acute liver damage, the
expression of CB1 and CB2 is enhanced, and the degree and
duration of inﬂammation may be an important factor for
controlling CB1 expression or activation of the cannabinoid
system. However, in a quantiﬁcation assay using real-time
polymerasechainreaction,CB1geneexpressionwasverylow
in liver samples from CH-C patients and healthy individuals
(unpublished data). In patients with CH-C, more severe
inﬂammation or ﬁbrosis may be needed to activate the
cannabinoid system.
As described above, there is a discrepancy between in
vitro data in HCV replicon cells and ﬁndings in the liver of
patients with CH-C. Therefore, it is questionable whether
activation of the cannabinoid system signiﬁcantly aﬀects
metabolic disorders in the HCV-infected liver. Of note,
someresearchershaveproposedtheexistenceofcannabinoid
receptors other than CB1 and CB2 and endocannabinoids
other than anandamide and 2-AG [52], although these
have not yet been clearly detected. Therefore, still unknown
cannabinoids and/or receptors may play a leading role in
hepatic metabolic disorders in patients with CH-C.
5.TherapeuticStrategiesUsing
Metabolic Modulators
Clinically, antioxidants, such as ursodeoxycholic acid and
vitamin E, have been commonly used for NAFLD and CH-
C patients as a liver supporting therapy. In many patients
withinsulinresistance,insulinsensitizers,suchasmetformin
and thiazolidinediones, have shown improving eﬀect of
liver biochemistry. Nowadays, IFN-based radical antiviral
treatments are generally accepted for patients with CH-C.
Hepatic steatosis and insulin resistance are negative predic-
tors for sustained virological response (SVR) in patients with4 International Journal of Hepatology
CH-C treated with peg-IFNα plus ribavirin combination
therapy [53, 54]. In recent meta-analyses, HOMA-IR, a
marker of insulin resistance, is negatively correlated with
SVR, irrespective of viral genotype [55, 56]. Therefore,
lifestyle modiﬁcations, such as weight reduction by exercise
and nutritional management, are recommended to enhance
the eﬀects of antiviral treatments. Moreover, it is justiﬁable
that the use of agents targeting insulin resistance and
dyslipidemia can improve the SVR rate achieved with IFN-
based antiviral treatments.
Insulin sensitizers, metformin and thiazolidinediones,
may increase the response to antiviral treatments [57].
In a recent clinical trial of insulin-resistant patients with
CH-C genotype 1, adding metformin to standard peg-
IFNα plus ribavirin therapy improved insulin sensitivity.
Metformin also tended to improve SVR, particularly in
females, although a statistically signiﬁcant diﬀerence was not
seen compared with patients receiving placebo [58]. Mean-
while, the eﬀects of pioglitazone on SVR in patients with
CH-C and insulin resistance are controversial. Pioglitazone
combined with peg-IFNα plus ribavirin therapy was used
as retreatment and in treatment-na¨ ıve patients, but results
of two pilot trials were disappointing [59, 60]. However,
somereportshavedescribedthattheadditionofpioglitazone
to standard therapy improves SVR and insulin sensitivity
[61, 62]. This discrepancy may be explained, at least in part,
by genotype dependency and host characteristics.
As described above, the synthesis of cholesterol and fatty
acids is still activated in the liver of patients with CH-C,
despitelipidoveraccumulation.Therefore,correctingcholes-
terol and fatty acid synthesis by lipid modulators may help to
reduce steatosis and improve SVR with antiviral treatments.
Considering that cholesterol synthesis is enhanced in HCV-
infected liver, it is plausible that HMGR inhibitors (statins)
could have antiviral eﬀects, because statins were recently
reported to suppress HCV replication [63]. In fact, it was
reported that statins do impede HCV replication by inhibit-
ing host protein geranylgeranylation, and FBL2 has been
identiﬁed as a geranylgeranylated cellular protein required
for HCV RNA replication [64]. Retrospective analyses of
patients with CH-C treated with peg-IFN plus ribavirin
combination therapy have shown that serum cholesterol and
the use of statins are positive predictors of SVR [65, 66].
In clinical trials, SVR was improved by adding ﬂuvastatin
or pitavastatin to peg-IFN plus ribavirin treatment [67–
69]. Although antiviral activity has been experimentally
demonstrated in most statins without pravastatin [63], a
statin with a more activity may achieve better SVR rates. Of
note, protease inhibitors, such as telaprevir, and statins taken
together may raise the blood levels of statins and increase
the risk of myopathy, kidney damage, and kidney failure. It
was also reported that polyunsaturated fatty acids (PUFAs)
inhibit HCV replication by a still unclear mechanism,
independent of their roles in regulating lipogenesis and that
eicosapentaenoic acid (EPA), an n-3 PUFA, inhibits HCV
replication in the replicon system and suppresses SREBP-
1c activity [70–72]. Additionally, administration of EPA
allows maintenance of the original ribavirin dose in patients
with CH-C during peg-IFN plus ribavirin combination
therapy [73]. Using HCV replicon systems, it was reported
that statins and EPA have suppressive eﬀects against HCV
replication and synergistic antiviral action with IFN [37, 70,
71, 74, 75].
Based on experimental and therapeutic evidence, con-
comitant administration of a statin and EPA with peg-IFN
plus ribavirin therapy is pathophysiologically promising for
patients with CH-C. Accordingly, we are now performing a
clinical trial using a new antiviral strategy for patients with
CH-Cgenotype1binwhichpitavastatin(2mg/day)andEPA
(1,800mg/day) are added to standard peg-IFN plus ribavirin
therapy. According to recent clinical studies of patients with
CH-C genotype-1b, mutation of amino acids 70 and 91 in
the core region of HCV-1b, as a virus-related factor, and
genomic variation of the IL28B gene (rs8099917), as a host-
related factor, are strong predictors of the outcome of peg-
IFN plus ribavirin combination therapy [76–79]. Within
the core protein, substitution of amino acid 70 seems to
be more inﬂuential on the outcome than substitution of
amino acid 91 [79–81]. At present, our trial has yielded
several important ﬁndings (unpublished data). First, add-on
pitavastatin and EPA therapy conferred signiﬁcantly higher
SVRratesthandidstandardtherapy.Second,add-ontherapy
signiﬁcantly improved SVR rates, particularly in patients
with the minor variant (TG + GG) of IL28B (rs8099917),
in whom SVR is expected to be poor. Of note, among
patients treated with add-on therapy, genomic variation of
IL28Bstillpredictsclinicaloutcomes,becauseSVRrateswere
signiﬁcantly higher in patients with the major variant (TT)
than in those with minor variants. Third, mutation of core
amino acid 70, which is a strong negative predictor of SVR
in standard peg-IFN plus ribavirin therapy, did not diminish
the outcomes of add-on therapy.
6. Conclusions
Steatosis and insulin resistance induced by HCV infection
are, at least in part, critical factors for the progression
of CH-C and can inﬂuence the outcome of antiviral
treatments. Therefore, managing these metabolic disorders
by administering insulin sensitizers and lipid modulators
has been examined to increase the therapeutic response
of standard treatments. In particular, concomitant treat-
ment with pitavastatin and EPA may achieve considerable
improvements in the eﬃcacy of peg-IFN plus ribavirin
combination therapy, particularly in patients with CH-C
resistant to standard peg-IFN plus ribavirin therapy.
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